Citric acid
Clenpiq, G, Idkit:hp, Phexxi, Renacidin (citric acid) is a small molecule pharmaceutical. Citric acid was first approved as Irrigating solution g in plastic container on 1982-06-22. It is used to treat renal tubular acidosis and urination disorders in the USA. It is known to target polycystic kidney disease 2-like 1 protein, transient receptor potential cation channel subfamily V member 4, and nectin-1.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| hereditary congenital and neonatal diseases and abnormalities | D009358 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Combinations
Clenpiq, Idkit:hp, Phexxi, Renacidin (generic drugs available since 2022-07-18, discontinued: Irrigating solution g, Prepopik, Urologic g)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Citric acid
+
Gluconolactone
+
Magnesium carbonate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RENACIDIN | United Guardian | N-019481 RX | 1990-10-02 | 1 products, RLD, RS |
Citric acid
+
Lactic acid
+
Potassium bitartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PHEXXI | Evofem Biosciences | N-208352 RX | 2020-05-22 | 1 products, RLD, RS |
Citric acid
+
Magnesium oxide
+
Sodium carbonate
Citric acid
+
Magnesium oxide
+
Sodium picosulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CLENPIQ | Ferring Pharmaceuticals | N-209589 RX | 2017-11-28 | 1 products, RLD, RS |
Show 1 discontinued
Citric acid
+
Urea c-13
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| IDKIT:HP | MERIDIAN BIOSCIENCE | N-021314 RX | 2002-12-17 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clenpiq | New Drug Application | 2023-01-04 |
| idkit hp one | New Drug Application | 2020-01-02 |
| phexxi | New Drug Application | 2022-02-11 |
| renacidin | New Drug Application | 2019-12-17 |
| sodium citrate and citric acid | unapproved drug other | 2023-06-13 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CITRIC ACID / LACTIC ACID / POTASSIUM BITARTRATE, PHEXXI, EVOFEM INC | |||
| 2023-05-22 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Citric Acid / Magnesium Oxide / Sodium Picosulfate, Clenpiq, Ferring Pharms Inc | |||
| 9827231 | 2034-06-26 | DP | U-2162 |
| 10624879 | 2034-06-23 | DP | |
| 11191753 | 2034-06-23 | U-3261 | |
| Citric Acid / Lactic Acid / Potassium Bitartrate, Phexxi, Evofem Inc | |||
| 10568855 | 2033-03-15 | U-1 | |
| 11337989 | 2033-03-15 | U-1 | |
| 11439610 | 2033-03-15 | DS, DP | |
| 6706276 | 2023-09-06 | DP | |
| Citric Acid / Magnesium Oxide / Sodium Picosulfate, Prepopik, Ferring Pharms Inc | |||
| 8450338 | 2028-10-10 | DP | |
| 8481083 | 2028-10-10 | DP | |
HCPCS
No data
Clinical
Clinical Trials
745 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 5 | 31 | 49 | 1 | 6 | 91 |
| Infertility | D007246 | EFO_0000545 | 4 | 10 | 11 | 18 | 11 | 47 | |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 1 | 8 | 10 | 13 | 12 | 41 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | 21 | 5 | 27 | |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 2 | 1 | 4 | 15 | 3 | 24 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | 6 | 6 | 5 | 18 |
| Healthy volunteers/patients | — | 11 | — | 2 | 1 | 2 | 16 | ||
| Hyperphosphatemia | D054559 | HP_0002905 | 1 | 1 | 9 | 4 | 1 | 16 | |
| Acute kidney injury | D058186 | HP_0001919 | N17 | 1 | — | 2 | 4 | 7 | 14 |
| Apnea | D001049 | HP_0002104 | R06.81 | 1 | 1 | 4 | 3 | 4 | 13 |
Show 76 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | C90.0 | 9 | 13 | 2 | — | — | 20 | |
| Neoplasms | D009369 | C80 | 1 | 4 | 1 | — | 3 | 9 | |
| Prostatic neoplasms | D011471 | C61 | 1 | 1 | 3 | — | 2 | 7 | |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 2 | 1 | — | 1 | 5 |
| Hypogonadism | D007006 | E23.0 | — | 4 | 1 | — | — | 5 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | 1 | — | 3 | 5 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | 2 | — | 1 | 5 | |
| Cancer pain | D000072716 | G89.3 | — | — | 5 | — | — | 5 | |
| Covid-19 | D000086382 | U07.1 | 1 | 3 | 1 | — | — | 4 | |
| Ductal carcinoma breast | D018270 | — | 2 | 1 | — | 1 | 4 |
Show 37 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | 1 | 5 | — | — | 1 | 7 | ||
| Male breast neoplasms | D018567 | — | 4 | — | — | 1 | 5 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 2 | — | — | 1 | 4 |
| Glioma | D005910 | EFO_0000520 | — | 2 | — | — | 1 | 3 | |
| Waldenstrom macroglobulinemia | D008258 | C88.0 | — | 3 | — | — | — | 3 | |
| Sarcoma | D012509 | 1 | 1 | — | — | 1 | 3 | ||
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | 1 | — | — | 2 | 3 |
| Iron deficiencies | D000090463 | E61.1 | — | 1 | — | — | 2 | 3 | |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 1 | 2 | — | — | — | 3 |
| Intracranial vasospasm | D020301 | EFO_1000994 | G45.9 | 1 | 2 | — | — | — | 3 |
Show 79 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | — | — | — | 2 | 3 |
| Biological availability | D001682 | 1 | — | — | — | 2 | 3 | ||
| Brain hypoxia-ischemia | D020925 | EFO_1000846 | P91.6 | 2 | — | — | — | — | 2 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 1 | — | — | — | 1 | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | 1 | 2 |
| Dental caries | D003731 | EFO_0003819 | K02 | 1 | — | — | — | 1 | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Blast crisis | D001752 | 1 | — | — | — | — | 1 | ||
| Hand-foot syndrome | D060831 | EFO_1001893 | 1 | — | — | — | — | 1 | |
| Leiomyoma | D007889 | HP_0000131 | D25 | 1 | — | — | — | — | 1 |
Show 12 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cough | D003371 | HP_0012735 | R05 | — | — | — | — | 4 | 4 |
| Continuous renal replacement therapy | D000079664 | — | — | — | — | 3 | 3 | ||
| Hyperinsulinism | D006946 | HP_0000842 | E16.1 | — | — | — | — | 2 | 2 |
| Inflammation | D007249 | — | — | — | — | 2 | 2 | ||
| Pregnancy complications | D011248 | — | — | — | — | 2 | 2 | ||
| Vascular stiffness | D059289 | — | — | — | — | 2 | 2 | ||
| Gingival recession | D005889 | K06.0 | — | — | — | — | 2 | 2 | |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | — | 1 | 1 |
| Wheelchairs | D014910 | — | — | — | — | 1 | 1 | ||
| Dietary supplements | D019587 | — | — | — | — | 1 | 1 |
Show 59 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CITRIC ACID |
| INN | dimpylate |
| Description | Idkit:hp (citric acid) is a small molecule pharmaceutical. Citric acid was first approved as Idkit:hp on 2002-12-17. It is used to treat renal tubular acidosis and urination disorders in the USA. It is known to target polycystic kidney disease 2-like 1 protein, transient receptor potential cation channel subfamily V member 4, and nectin-1. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)CC(O)(CC(=O)O)C(=O)O |
Identifiers
| PDB | 3ALP |
| CAS-ID | 77-92-9 |
| RxCUI | 21183 |
| ChEMBL ID | CHEMBL1261 |
| ChEBI ID | 30769 |
| PubChem CID | 311 |
| DrugBank | DB04272 |
| UNII ID | YUS1M1Q929 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PKD2L1
PKD2L1
TRPV4
TRPV4
NECTIN1
NECTIN1
Organism
Homo sapiens
Gene name
PKD2L1
Gene synonyms
PKD2L, PKDL, TRPP3
NCBI Gene ID
Protein name
polycystic kidney disease 2-like 1 protein
Protein synonyms
Polycystin-2 homolog, Polycystin-2L1, Polycystin-L, Polycystin-L1, transient receptor potential cation channel, subfamily P, member 3
Uniprot ID
Mouse ortholog
Pkd2l1 (329064)
polycystic kidney disease 2-like 1 protein (Q80ZH4)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 93,968 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,594 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more